Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 02, 2017 16:30 ET | Source: Esperion Therapeutics, Inc.

Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid

– Pivotal Phase 3 Top-Line Results for Bempedoic Acid Expected in the Second and Third Quarters of 2018 –– NDA Submission for LDL-C Lowering Indication for Bempedoic Acid Planned by First Quarter 2019...